- Start date: 01/11/17
- End date: 31/10/19
- Value: £227,550.17 (University of Leeds)
- Partners and collaborators: Randox
- Primary investigator: Rosamonde Banks
- Co-investigators: Beth Shinkins
Chronic kidney disease (CKD) affects 10-15% of the adult population. Progression to end stage kidney disease (ESKD) is a leading cause of morbidity and mortality worldwide with 2.6 million people receiving renal replacement therapy (dialysis or transplantation) in 2010. Numbers continue to increase markedly as a result of the global epidemics of type 2 diabetes and hypertension in particular which are linked with causing CKD. Kidney transplantation is the optimal treatment for ESKD with almost 80,000 transplants annually worldwide, with significantly better survival, major cost savings and quality of life compared with dialysis. Increasingly, to meet demand, kidneys are used from deceased donors after circulatory death and more marginal donors and overall ~80% of kidney transplants in the EU are from deceased donors. However, these have complications such as delayed graft function (DGF; when the transplanted kidney fails to work adequately in the first week following transplant) which affects 30-40% of patients and has a higher risk of mortality, transplant loss and increased hospital stay.
The main overarching aim of this proposal is to manufacture and independently clinically validate an innovative multiplex biomarker assay (Renal Transplant Panel) which includes our novel validated biomarker aminoacylase-1. It will be assessed in terms of a). prediction/earlier diagnosis of complications post-transplant and b). long-term prognostic information and an associated health economic evaluation will be undertaken in parallel.